Nifty
Sensex
:
:
17853.20
60048.47
30.25 (0.17%)
163.11 (0.27%)

Pharmaceuticals & Drugs - API

Rating :
50/99

BSE: 530239 | NSE: SUVEN

100.10
24-Sep-2021
  • Open
  • High
  • Low
  • Previous Close
  •  100.50
  •  102.40
  •  98.10
  •  99.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1283401
  •  1284.21
  •  116.00
  •  43.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,271.55
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,226.24
  • N/A
  • 39.89

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.00%
  • 1.40%
  • 34.22%
  • FII
  • DII
  • Others
  • 0.41%
  • 0.01%
  • 3.96%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -23.80
  • -52.26
  • -63.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 48.74

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 44.53

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.48
  • 25.47
  • 5.61

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.64
  • 5.66
  • 6.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.85
  • 8.34
  • 3.25

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
2.01
1.43
40.56%
1.56
8.66
-81.99%
1.51
2.77
-45.49%
8.98
1.39
546.04%
Expenses
44.58
15.65
184.86%
23.14
33.73
-31.40%
28.12
30.44
-7.62%
26.57
22.47
18.25%
EBITDA
-42.58
-14.22
-
-21.58
-25.07
-
-26.61
-27.67
-
-17.59
-21.08
-
EBIDTM
-2,122.43%
-995.45%
-1,386.19%
-289.51%
-1,758.56%
-997.84%
-195.90%
-1,519.97%
Other Income
4.55
2.53
79.84%
1.32
3.00
-56.00%
1.62
5.85
-72.31%
2.28
2.38
-4.20%
Interest
0.15
0.20
-25.00%
0.24
0.23
4.35%
0.18
0.10
80.00%
0.26
0.11
136.36%
Depreciation
1.03
1.06
-2.83%
1.07
1.05
1.90%
1.14
0.86
32.56%
1.07
1.42
-24.65%
PBT
-39.21
-12.96
-
-21.57
-23.36
-
-26.30
-22.77
-
-16.65
-20.23
-
Tax
0.00
-2.47
-
0.05
2.20
-97.73%
-1.91
0.04
-
-0.99
-0.41
-
PAT
-39.21
-10.49
-
-21.61
-25.56
-
-24.39
-22.81
-
-15.66
-19.81
-
PATM
-1,954.54%
-734.08%
-1,388.18%
-295.12%
-1,612.16%
-822.72%
-174.34%
-1,428.55%
EPS
-3.08
-0.82
-
-1.70
-2.01
-
-1.92
-1.79
-
-1.23
-1.56
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Net Sales
14.06
13.48
14.41
285.67
625.26
543.53
499.52
520.86
117.28
111.92
88.08
Net Sales Growth
-1.33%
-6.45%
-94.96%
-54.31%
15.04%
8.81%
-4.10%
344.12%
4.79%
27.07%
 
Cost Of Goods Sold
0.00
0.00
0.00
68.74
152.17
147.06
162.64
177.61
44.18
42.04
30.66
Gross Profit
14.06
13.48
14.41
216.93
473.09
396.47
336.88
343.25
73.10
69.88
57.42
GP Margin
99.97%
100%
100%
75.94%
75.66%
72.94%
67.44%
65.90%
62.33%
62.44%
65.19%
Total Expenditure
122.41
93.42
130.13
296.65
423.61
414.46
398.18
361.40
104.61
95.57
77.29
Power & Fuel Cost
-
0.00
1.63
19.37
33.56
31.50
29.32
28.04
7.95
6.34
5.77
% Of Sales
-
0%
11.31%
6.78%
5.37%
5.80%
5.87%
5.38%
6.78%
5.66%
6.55%
Employee Cost
-
18.53
17.41
36.49
61.27
52.17
35.64
31.75
12.25
9.53
7.37
% Of Sales
-
137.46%
120.82%
12.77%
9.80%
9.60%
7.13%
6.10%
10.45%
8.52%
8.37%
Manufacturing Exp.
-
71.16
103.25
147.09
144.07
153.86
139.49
95.91
29.74
27.89
25.17
% Of Sales
-
527.89%
716.52%
51.49%
23.04%
28.31%
27.92%
18.41%
25.36%
24.92%
28.58%
General & Admin Exp.
-
3.31
4.96
13.48
20.66
19.45
22.48
20.14
8.38
7.53
5.85
% Of Sales
-
24.55%
34.42%
4.72%
3.30%
3.58%
4.50%
3.87%
7.15%
6.73%
6.64%
Selling & Distn. Exp.
-
0.00
0.00
4.89
8.57
7.46
6.73
5.17
2.06
2.15
1.58
% Of Sales
-
0%
0%
1.71%
1.37%
1.37%
1.35%
0.99%
1.76%
1.92%
1.79%
Miscellaneous Exp.
-
0.41
2.88
6.59
3.31
2.95
1.88
2.77
0.05
0.10
1.58
% Of Sales
-
3.04%
19.99%
2.31%
0.53%
0.54%
0.38%
0.53%
0.04%
0.09%
1.00%
EBITDA
-108.36
-79.94
-115.72
-10.98
201.65
129.07
101.34
159.46
12.67
16.35
10.79
EBITDA Margin
-770.70%
-593.03%
-803.05%
-3.84%
32.25%
23.75%
20.29%
30.61%
10.80%
14.61%
12.25%
Other Income
9.77
7.75
14.04
27.25
23.27
21.09
19.62
8.58
3.18
1.46
0.82
Interest
0.83
0.94
0.55
1.91
4.63
5.68
5.88
4.71
5.06
3.03
1.65
Depreciation
4.31
4.35
4.17
14.20
24.76
21.41
17.50
11.78
4.44
4.01
3.46
PBT
-103.73
-77.47
-106.40
0.16
195.53
123.07
97.58
151.55
6.36
10.76
6.49
Tax
-2.85
-5.32
-12.18
24.06
71.84
35.88
25.74
42.80
-1.99
-0.51
0.11
Tax Rate
2.75%
6.87%
11.45%
15037.50%
36.74%
29.15%
26.38%
28.24%
-31.29%
-4.74%
1.69%
PAT
-100.87
-72.15
-94.22
-23.90
123.69
87.19
71.85
108.75
8.35
11.26
6.39
PAT before Minority Interest
-100.87
-72.15
-94.22
-23.90
123.69
87.19
71.85
108.75
8.35
11.26
6.39
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-717.43%
-535.24%
-653.85%
-8.37%
19.78%
16.04%
14.38%
20.88%
7.12%
10.06%
7.25%
PAT Growth
0.00%
-
-
-
41.86%
21.35%
-33.93%
1,202.40%
-25.84%
76.21%
 
EPS
-7.92
-5.67
-7.40
-1.88
9.72
6.85
5.64
8.54
0.66
0.88
0.50

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Shareholder's Funds
108.01
143.35
239.13
767.41
667.00
595.28
559.31
106.39
101.52
90.21
Share Capital
12.73
12.73
12.73
12.73
12.73
12.73
12.73
11.57
5.76
5.00
Total Reserves
58.36
130.62
226.40
754.68
654.27
582.56
546.59
94.82
95.76
85.21
Non-Current Liabilities
4.50
12.07
24.51
30.20
28.21
40.54
86.43
57.06
46.78
30.83
Secured Loans
0.00
0.00
0.00
0.25
22.65
37.08
55.09
54.62
41.49
23.68
Unsecured Loans
0.39
1.08
1.78
1.98
3.29
4.56
6.36
0.00
0.00
0.00
Long Term Provisions
1.73
1.72
1.49
3.69
2.84
2.39
2.27
0.00
0.00
0.00
Current Liabilities
109.81
120.03
156.97
225.83
208.05
210.62
127.39
35.08
24.95
21.98
Trade Payables
3.00
5.78
7.09
56.82
37.94
35.60
43.89
20.14
11.87
11.63
Other Current Liabilities
12.13
20.00
32.00
29.43
46.14
48.18
42.45
0.63
1.06
0.29
Short Term Borrowings
0.00
0.00
0.00
30.57
30.49
24.16
28.24
0.00
0.00
0.00
Short Term Provisions
94.68
94.25
117.88
109.01
93.49
102.68
12.81
14.32
12.02
10.07
Total Liabilities
222.32
275.45
420.61
1,023.44
903.26
846.44
773.13
198.53
173.25
143.02
Net Block
20.96
24.69
22.35
307.73
305.72
305.35
171.95
109.77
95.62
82.77
Gross Block
67.77
77.11
39.48
375.68
348.92
325.15
290.52
141.20
120.47
101.64
Accumulated Depreciation
46.81
52.42
17.13
67.95
43.19
19.80
118.57
31.43
24.86
18.87
Non Current Assets
25.74
115.95
22.37
349.61
322.10
318.79
291.31
115.72
105.60
89.53
Capital Work in Progress
4.77
0.00
0.02
24.74
9.72
7.20
107.01
3.66
5.02
2.67
Non Current Investment
0.00
0.00
0.00
0.07
0.07
0.07
0.00
2.29
4.96
4.09
Long Term Loans & Adv.
0.00
91.25
0.00
16.86
6.39
6.16
10.89
0.00
0.00
0.00
Other Non Current Assets
0.00
0.00
0.00
0.20
0.20
0.00
1.46
0.00
0.00
0.00
Current Assets
196.58
159.50
398.24
673.83
581.16
527.66
476.98
82.79
67.60
53.43
Current Investments
0.09
0.05
222.93
278.73
300.89
0.05
0.04
0.00
0.00
0.00
Inventories
0.14
0.00
0.00
139.47
92.51
83.46
81.81
24.40
22.90
22.74
Sundry Debtors
1.76
2.27
2.64
61.54
45.83
53.56
40.17
35.59
16.14
14.99
Cash & Bank
46.65
15.09
0.69
28.22
9.17
241.40
279.69
3.04
9.78
1.37
Other Current Assets
147.94
1.37
2.78
50.35
132.76
149.18
75.28
19.77
18.79
14.33
Short Term Loans & Adv.
141.25
140.72
169.20
115.53
99.87
108.96
34.06
14.93
14.33
9.70
Net Current Assets
86.77
39.48
241.27
448.00
373.11
317.04
349.59
47.71
42.65
31.45
Total Assets
222.32
275.45
420.61
1,023.44
903.26
846.45
773.14
198.53
173.24
143.02

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 08
Mar 07
Mar 06
Mar 05
Cash From Operating Activity
-96.02
-134.57
-52.61
69.94
109.17
67.50
3.94
16.24
5.51
2.11
PBT
-77.47
-106.40
0.16
195.53
123.07
97.58
6.36
10.76
6.49
5.79
Adjustment
-2.70
-8.26
-4.87
10.32
12.91
10.98
11.22
6.54
6.56
3.97
Changes in Working Capital
-14.70
-17.13
-32.98
-92.37
7.90
-14.36
-12.96
0.46
-6.52
-6.95
Cash after chg. in Working capital
-94.88
-131.79
-37.70
113.47
143.88
94.20
4.63
17.75
6.54
2.81
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1.15
-2.78
-14.92
-43.54
-34.71
-26.70
-0.69
-1.51
-1.03
-0.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
55.84
146.22
37.13
-0.61
-310.64
-38.63
-16.20
-20.46
-9.45
-4.11
Net Fixed Assets
4.57
-37.61
360.92
-41.78
-26.29
-187.49
-19.37
-21.18
-13.51
Net Investments
-53.26
117.43
21.74
-15.06
-342.87
-14.91
2.67
-0.87
4.00
Others
104.53
66.40
-345.53
56.23
58.52
163.77
0.50
1.59
0.06
Cash from Financing Activity
34.86
2.81
4.53
-52.07
-30.39
-68.07
5.52
12.62
2.73
-7.51
Net Cash Inflow / Outflow
-5.33
14.45
-10.94
17.26
-231.86
-39.20
-6.74
8.40
-1.20
-9.51
Opening Cash & Equivalents
14.68
0.23
17.89
8.69
240.55
279.75
9.78
1.37
2.57
12.09
Closing Cash & Equivalent
9.35
14.68
0.23
25.95
8.69
240.55
3.04
9.78
1.37
2.57

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 08
Mar 07
Mar 06
Book Value (Rs.)
5.58
11.26
18.79
60.29
52.40
46.77
43.56
9.19
35.21
9.01
ROA
-28.99%
-27.07%
-3.31%
12.84%
9.97%
8.87%
22.38%
4.49%
7.12%
4.58%
ROE
-67.29%
-49.27%
-4.75%
17.25%
13.81%
12.50%
32.91%
8.04%
11.76%
7.46%
ROCE
-60.09%
-54.67%
0.40%
26.01%
18.19%
15.43%
37.93%
7.51%
10.74%
7.59%
Fixed Asset Turnover
0.19
0.25
1.38
1.73
1.62
1.63
2.42
0.92
1.02
0.95
Receivable days
54.60
62.22
41.00
31.34
33.32
34.19
26.51
78.68
50.16
68.08
Inventory Days
3.83
0.00
0.00
67.71
58.98
60.29
37.16
71.95
73.54
85.16
Payable days
16.88
18.53
39.04
38.79
33.17
35.72
32.74
57.23
45.77
52.98
Cash Conversion Cycle
41.55
43.70
1.96
60.26
59.13
58.77
30.93
93.40
77.93
100.27
Total Debt/Equity
0.02
0.01
0.01
0.04
0.11
0.14
0.20
0.51
0.41
0.26
Interest Cover
-81.35
-191.96
1.08
43.25
22.65
17.61
33.18
2.26
4.55
4.93

Top Investors:

News Update:


  • Suven Life Sciences to start Phase 3 clinical trial of SUVN-502
    17th Aug 2021, 10:49 AM

    SUVN-502 has successfully undergone two phase 1 studies in Switzerland and USA on 122 healthy young

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.